New Drugs in the Treatment of Borderline Personality Disorder

  • F. Benedetti
  • C. Colombo
  • L. Sforzini
  • C. Maffei
  • E. Smeraldi


From both a clinical and a neurobiological point of view, Borderline Personality Disorder (BPD) as defined by DSM-IV (A.P.A., 1994) must be considered an heterogeneous condition. Clinical studies on BPD patients showed that BPD diagnosis is rarely the only Axis II diagnosis present in a personality disordered patient, and broadly overlaps with other diagnoses pertaining to the three DSM category clusters (e.g. Nurnberg et al., 1991). Moreover, comorbidity with Axis I pathologies is often present: as reported in DSM-IV itself, heterogenous Axis I pathologies (such as mood disorders, substance-related disorders, eating disorders, post-traumatic stress disorders, and attention-deficit disorder) are commonly diagnosed in patients affected by BPD.


Borderline Personality Disorder Personality Disorder Borderline Personality Disorder Borderline Personality Disorder Patient Impulsive Aggression 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Akiskal H.S., Chen S.E., Davis G.C., Puzantian V.R., Kashgarian M., and Bolinger J.M. (1985) Borderline: an adjective in search of a noun. J Clin Psychiatry 46: 41–48.PubMedGoogle Scholar
  2. American Psychiatric Association. Diagnostic and statistic manual of mental disorders. 4rd ed. Washington, DC: A.P.A. Press;1994.Google Scholar
  3. Andrulonis D.A., Glueck B.C., Stroebel C.F. et al. (1981) Organic brain dysfunction in the borderline syndrome. Psychiatr Clin North Am 4:47–66.PubMedGoogle Scholar
  4. Barratt E.S., Kent T.A., Bryant S.G. et al. (1991) A controlled trial of phenytoine in impulsive aggression (letter) J Clin Psychopharmacol 11: 388–389.Google Scholar
  5. Battaglia M., Perini Strambi L., Smirne S., Bernardeschi L., and Bellodi L. (1993) Ambulatory polysomnography of never-depressed borderline subjects: a high-risk approach to rapid eye movement latency. Biol Psychiatry 33: 326–334.PubMedCrossRefGoogle Scholar
  6. Battaglia M., Ferini Strambi L., Smirne S., Bemardeschi L., Oldani L., and Bellodi L. (1995) Cardiac autonomic fonction during sleep of never-depressed bordeline subjects: a pilot study. J Psychiatric Res 29: 397–405.CrossRefGoogle Scholar
  7. Battaglia M., Ferini Strambi L., Bertella S., Bajo S., and Bellodi L. (1998) First-cycle REM density in never-depressed subjects with borderline personality disorder. Biol Psychiatry, in press.Google Scholar
  8. Bellodi L., Battaglia M., Gasperini M., Scherillo P., and Brancato V. (1992) The nature of depression in borderline depressed patients. Compr Psychiatry 33: 128–133.PubMedCrossRefGoogle Scholar
  9. Benedetti E, Sforzini L., Colombo C., Maffei C., and Smeraldi E. (1998) Low-dose clozapine in acute and continuation treatment of severe borderline personality disorder. J Clin Psychiatry 59: 103–107.PubMedCrossRefGoogle Scholar
  10. Bolton S. and Gunderson J.G. (1996) Distinguishing bordeline personality disorder from bipolar disorder: differential diagnosis and implications. Am J Psychiatry 153: 1202–1207.PubMedGoogle Scholar
  11. Brinkley J.R., Beitman B.D., and Friedel R.O. (1979) Low-dose neuroleptic regims in the treatment of borderline patients. Arch Gen Psychiatry 36: 319–326.PubMedCrossRefGoogle Scholar
  12. Casey P., Meagher D., and Butler E. (1996) Personality, functioning, and recovery from major depression. J Nery Ment Dis 184 (Suppl 4): 240–245.CrossRefGoogle Scholar
  13. Chengappa K.N.R., Baker R.W., and Sirri C. (1995) The successful use of clozapine in ameliorating severe self mutilation in a patient with borderline personality disorder. J Personality Disord 9 (1): 76–82.CrossRefGoogle Scholar
  14. Chopra H.D. and Beatson T.A. (1986) Psychotic Symptoms in Borderline Personality Disorder. Am J Psy-chiatry 143: 12.Google Scholar
  15. Coccaro E.F. (1989) Central serotonin and impulsive aggression. Br J Psychiatry 155: 52–62.Google Scholar
  16. Coccaro E.E, Siever L.J., Klar H.M., Maurer G., Cochrane K., Cooper T.B., Mohs R.C., and Davis K.L. (1989a) Serotonergic studies in patients with affective and personality disorders: correlates with suicidal and impulsive aggressive behavior. Arch Gen Psychiatry 46: 587–599.PubMedCrossRefGoogle Scholar
  17. Coccaro E.F., Siever L.J., Kavoussi R., and Davis K.L. (1989b) Impulsive aggression in personality disorder: evidence for involvment of 5HT1 receptors. Biol Psychiatry (Suppl) 25 (7A): 86A.CrossRefGoogle Scholar
  18. Coccaro E.F., Astill J.L., Herbert J.L., and Schut A.J. (1990) Fluoxetine treatment of impulsive aggression in DSM-IIIR personality disorder patients. J Clin Psychopharmacol 10: 373–375.PubMedCrossRefGoogle Scholar
  19. Coccaro E.F. and Siever L.J. (1995) The neuropsychopharmacology of personality disorders. In: Bloom F.E. and Kupfer D.J., eds. Psychopharmacology: the fourth generation of progress. New York: Raven Press; pp. 1567–1578.Google Scholar
  20. Coccaro E.F. (1998) Clinical outcome of psychopharmacologie treatment of borderline and schizotypal personality disordered subjects. J Clin Psychiatry 59 (Suppl 1): 30–35.PubMedCrossRefGoogle Scholar
  21. Cornelius J.R., Soloff P.H., Perel J.M., and Ulrich R.F. (1990) Fluoxetine trial in borderline personality disorder. Psychopharmacol Bull 26: 151–154.PubMedGoogle Scholar
  22. Cornelius J.R., Soloff P.H., Perel J.M., and Ulrich R.F. (1993) Continuation pharmacotherapy of borderline personality disorder with haloperidol and phenelzine Am J Psychiatry 150: 1843–1848.Google Scholar
  23. Coryell W.H. and Zimmerman M. (1989) Personality disorder in the families of depressed, schizophrenic and never-ill probands. Am J Psychiatry 146: 496–502.PubMedGoogle Scholar
  24. Cowdry R.W., Pickard D., and Davies R. (1980) Limbic dysfunction in the borderline syndrome. In: New research abstracts,133rd annual meeting of american psychiatric association. Washington, DC, A.P.A. Press.Google Scholar
  25. Cowdry R.W. (1987) Psychopharmacology of Borderline Personality Disorder: A Review. J Clin Psychiatry 48 (Suppl 8): 15–22.PubMedGoogle Scholar
  26. Cowdry R.W. and Gardner D.L. (1988) Pharmacotherapy of borderline personality disorder: alprazolam, carbamazepine, trifluoperazine, tranylcypromine. Arch Gen Psychiatry 45: 111–119.PubMedCrossRefGoogle Scholar
  27. De la Fuente J.M. and Lotstra F. (1994) A trial of carbamazepine in borderline personality disorder. European Neuropsychopharmacol 4 (4): 479–486.CrossRefGoogle Scholar
  28. De la Fuente J.M., Tugendhaft P., and Mavroudakis N. (1998) Electroenceplialographic abnormalities in borderline personality disorder. Psychiatry Res 77: 131–138.PubMedCrossRefGoogle Scholar
  29. Faltus F.J. (1984) The positive effect of alprazolam in the treatment of three patients with borderline personality disorder. Am J Psychiatry 141: 802–803.PubMedGoogle Scholar
  30. Frankenburg F.R. and Zanarini M.C. (1993) Clozapine treatment of borderline patients: a preliminary study. Comprenhens Psychiatry 34 (6): 402–405.CrossRefGoogle Scholar
  31. Gardner D.L. and Cowdry R.W. (1986) Positive effects of carbamazepine on behavioral dyscontrol in borderline personality disorder. Am J Psychiatry 143: 519–522.PubMedGoogle Scholar
  32. Gasperini M., Battaglia M., Scherillo P., Sciuto G., Diaferia G., and Bellodi L. (1991) Morbidity risk for mood disorders in the families of borderline patients. J Affective Disord 21: 265–272.CrossRefGoogle Scholar
  33. George A. and Soloff P.H. (1986) Schizotypal symptoms in patients with Borderline Personality Disorders. Am J Psychiatry 143: 2.Google Scholar
  34. Giakas W.J., Seibyl J.P., and Mazure C.M. (1990) Valproate in the treatment of temper outbursts (letter). J Clin Psychiatry 51: 525.PubMedGoogle Scholar
  35. Gitlin M.J. (1993) Pharmacotherapy of Personality Disorders: conceptual framework and clinical strategies. J Clin Psychopharmacol 13: 343–353.PubMedGoogle Scholar
  36. Goldberg S.C., Schulz C., Schulz P.M., Resnick R.J., Hamer R.M., and Friedel R.O. (1986) Borderline and schizotypal personality disorders treated with low-dose thiothixene versus placebo. Arch Gen Psychiatry 43: 680–686.PubMedCrossRefGoogle Scholar
  37. Gunderson J.G. and Phillips K.A. (1991) A current view of the interface between borderline personality disorder and depression. Am J Psichiatry 148: 8 967–975.Google Scholar
  38. Hasan M.Y., Sewell R.D.E., and Nicholls P.J. (1990) Does the anticonvulsant agent sodium valproate display behaviorally selective anti-offensive activity? (abstract) J Pharm Pharmacol 42 (Suppl): 185.Google Scholar
  39. Hirschfeld R.M. (1997) Pharmacotherapy of borderline personality disorder. J Clin Psychiatry 58 (Suppl14): 48–52.PubMedGoogle Scholar
  40. Hollander E., Stein D.J., DeCaria C.M., Cohen L., Saoud J.B., Skodol A.E., Kellman D., Rosnick L., and Oldham J.M. (1994) Serotonergic sensitivity in borderline personality disorder: preliminary findings. Am J Psychiatry 151: 2 277–280.PubMedGoogle Scholar
  41. Hull J.W., Clarkin J.E, and Alexopoulos G.S. (1993) Time series analysis of intervention effects. Fluoxetine therapy as a case illustration. J Nery Ment Dis 181: 48–53.Google Scholar
  42. Jonas J.M. and Pope H.G. (1984) Psychosis in borderline personality disorder. Psychiatr Dev 4:295–308. Kane J., Honigfeld G., Singer J., and Meltzer H. (1988) Clozapine for the treatment-resistant schizophrenia. Arch Gen Psychiatry 45: 789–796.Google Scholar
  43. Kavoussi R.J., Liu J., and Coccaro E.F. (1994) An open trial of sertraline in personality disordered patients with impulsive aggression. J Clin Psychiatry 55: 137–141.PubMedGoogle Scholar
  44. Keck EE., McElroy S.L., and Friedman L.M. (1992) Valproate and carbamazepine in the treatment of panic and post-traumatic stress disorders, withdrawal states, and behavioral dyscontrol syndromes. J Clin Psychopharmacol 12 (Suppl 1): 36–41.CrossRefGoogle Scholar
  45. Kutcher S., Papatheodorou G., Reiter S., and Gardner D. (1995) The successful pharmacological treatment of adolescents and young adults with borderline personality disorders: a preliminary open trial of flupenthixol. J Psychiat Neurosci 20: 113–118.Google Scholar
  46. Lahmeyer H.W., Reynolds C.F., Kupfer D.J., and King R. (1989) Biologic markers in borderline personality disorder: a review. J Clin Psychiatry 50: 217–225.PubMedGoogle Scholar
  47. Leone F.N. (1982) Response of borderline patients to loxapine and chlorpromazine J Clin Psychiatry 43: 148–150.Google Scholar
  48. Links P.S., Steiner M., and Huxley G. (1988) The occurence of borderline personality disorder in the families of borderline patients. J Personality Disord 2: 14–20.CrossRefGoogle Scholar
  49. Links P.S., Steiner M., Boiago I., and Irwin D. (1990) Lithium therapy for borderline patients: preliminary findings. J Personality Disord 4: 173–181.CrossRefGoogle Scholar
  50. Loranger A.W., Oldham J.M., and Tulis E.H. (1982) Familial transmission of borderline personality. Arch Gen Psychiatry 39: 795–802.PubMedCrossRefGoogle Scholar
  51. Markowitz P.J., Calabrese J.R., Schulz S.C., and Meltzer H.Y. (1991) Fluoxetine in the treatment of borderline and schizotypal personality disorders. Am J Psychiatry 148: 1064–1067.Google Scholar
  52. Mattes J. (1990) Comparative effectiveness of carbamazepine and propanolol for rage outbursts. J Neuropsychiatry Clin Neurosci 2: 159–164.PubMedGoogle Scholar
  53. Montgomery S.A. and Montgomery D. (1982) Pharmacological prevention of suicidal behavior. J Affect Disord 4: 291–298.PubMedCrossRefGoogle Scholar
  54. Montgomery S.A., Roy D., and Montgomery D.B. (1987) The prevention of recurrent suicidal acts. Br J Clin Pharmacol 15: 1835–1885.Google Scholar
  55. Moss H.B., Yao J.K., and Panzak L. (1990) Serotonergic responsivity and behavioral dimensions in antisocial personality disorder with substance abuse. Biol Psychiatry 28: 325–338.PubMedCrossRefGoogle Scholar
  56. Norden M.J. (1989) Fluoxetine in borderline personality disorder. Progr Neuropsychopharmacol Biol Psychiatry 13: 885–893.CrossRefGoogle Scholar
  57. Nurnberg H.G., Raskin M., Levine PE., Pollack S., Siegel O., and Prince R. (1991) The comorbidity of borderline personality disorder and other DSM-III-R Axis II personality disorders. Am J Psychiatry 148: 10 1371–1377.PubMedGoogle Scholar
  58. Pfohl B., Stangl D., and Zimmerman M. (1984) The implications of DSM III personality disorders for patients with major depression. J Affective Disord 7: 309–318.CrossRefGoogle Scholar
  59. Pope H.G., Jonas J.M., Hudson J.I., Cohen B.M., and Gunderson J.C. (1983) The validity of DSM-III borderline personality disorder. Arch Gen Psychiatry 40: 23–30.PubMedCrossRefGoogle Scholar
  60. Pope H.G., Jonas J.M., Hudson J.I., Cohen B.M., and Tohen M. (1985) An empirical study of psychosis in borderline personality disorder. Am J Psychiatry 142: 1285–1290.PubMedGoogle Scholar
  61. Rogers J.H., Wiediger T.A., and Krupp A. (1995) Aspects of depression associated with borderline personality disorder. Am J Psychiatry 152: 268–270.PubMedGoogle Scholar
  62. Rosenberg R. (1994) Borderline states: pharmacotherapy in psychobiology of personality. Acta Psychiatr Scand 89 (Suppl 379): 56–60.CrossRefGoogle Scholar
  63. Salzman C., Wolfson A.N., Schatzberg A., Looper J., Henke R., Albanese M., Schwartz J., and Miyawaki E. (1995) Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder. J Clin Psychopharmacol 15: 23–29.PubMedCrossRefGoogle Scholar
  64. Schulz P.M., Kelly T., Di Franco R. et al. (1986) Borderline personality disorder: family histories, in CME Syllabus and scientific Proceedings in Summary Form, 139th Annual Meeting of the American Psychiatric Association. Washington, DC, APA.Google Scholar
  65. Serban G. and Siegel S. (1984) Response of borderline and schizotypal patients to small doses of thiothixene and haloperidol. Am J Psychiatry 141: 1455–1458.PubMedGoogle Scholar
  66. Shader R.I., Jackson A.H., and Dodes L.M. (1974) The antiaggressive effect of lithium in man. Psychopharmacology 40: 17–24.CrossRefGoogle Scholar
  67. Shea M.T., Glass D.R., Pilkonis P.A. et al. (1987) Frequency and implications of personality disorders in a sample of depressed outpatients. J Personality Disord 1: 27–42.CrossRefGoogle Scholar
  68. Sheard M.H. (1975) Lithium in the treatment of aggression. J Nery Ment Dis 160: 108–118.CrossRefGoogle Scholar
  69. Skodal A., Buckley P, and Charles E. (1983) Is there a characteristic pattern to the treatment history of clinical outpatients with borderline personality? J Nery Ment Dis 171: 405–410.CrossRefGoogle Scholar
  70. Siever L.J., Amin F., Coccaro E.F., Bernstein D., Kavoussi R.J., Kalus O., Horvath T.B., Warne P, Davidson M., and Davis K.L. (1991) Plasma homovanillic acid in schizotypal personality disorder. Am J Psychiatry 148: 1246–1248.PubMedGoogle Scholar
  71. Siever L.J., Amin F., Coccaro E.F., Trestmann R., Silvermann J., Horvath T.B., Mahon T.R., Knott P., Altstiel L., Davidson M., and Davis K.L. (1993) CSF homovanillic acid in schizotypal personality disorder. Am J Psychiatry 150: 149–151.PubMedGoogle Scholar
  72. Silverman J.M., Pinkhan L., Horvath T.B., Coccaro E.F., Klar H., Shear S., Apter S., Davidson M., Mohs R.C., and Siever L.J. (1991) Affective and impulsive personality disorder traits in the relatives of borderline personality disorder. Am J Psychiatry 148: 1378–1385.PubMedGoogle Scholar
  73. Soloff P.H. and Millwdrd J.W. (1983) Psychiatric disorders in the families of borderline patients. Arch Gen Psychiatry 40: 37–44.PubMedCrossRefGoogle Scholar
  74. Soloff PH., George A., Nathan R.S., Schulz P.M., Ulrich R.F., and Perel J.M. (1986a) Progress in pharmacotherapy of borderline disorders. A double blind study of amitriptyline, haloperidol, and placebo. Arch Gen Psychiatry 43: 691–697.Google Scholar
  75. Soloff P.H., George A., Nathan R.S., Schulz P.M., and Perel J.M. (1986b) Paradoxical effects of amitriptyline on borderline patients. Am J Psychiatry 143: 12 1603–1605.PubMedGoogle Scholar
  76. Soloff PH., George A., Nathan R.S., Schulz P.M., Cornelius J.R., Herring J., and Perel J.M. (1989) Amitryptiline versus haloperidol in borderlines: final outcome and predictors of response. J Clin Psychopharmacol 9: 238–246.PubMedCrossRefGoogle Scholar
  77. Soloff PH., Cornelius J., George A., Nathan S., Perel J.M., and Ulrich R.E (1993) Efficacy of phenelzine and haloperidol in borderline personality disorder. Arch Gen Psychiatry 50: 377–385.PubMedCrossRefGoogle Scholar
  78. Soloff PH. (1994) Is there any drug treatment of choice for the borderline patient? Acta Psychiatr Scand 89 (Suppl 379): 50–55.CrossRefGoogle Scholar
  79. Southwick S.M., Yehuda R., and Giller E.L. (1995) Psychological dimensions of depression in borderline personality disorder. Am J Psychiatry 152: 789–791.PubMedGoogle Scholar
  80. Stein G. (1992) Drug treatment of the personality disorders. Br J Psychiatry 161: 167–184.PubMedCrossRefGoogle Scholar
  81. Stein M.R., Simeon D., Frenkel M., Islam M.N., and Hollander E. (1995) An open trial of valproate in borderline personality disorder. J Clin Psychiatry 56: 506–510.PubMedGoogle Scholar
  82. Steinert T., Schmidt-Michel P.O., and Kaschka W.P. (1996) Considerable improvement in a case of obsessive-compulsive disorder in an emotionally unstable personality disorder, borderline type, under treatment with clozapine. Pharmacopsychiatry 29: 111–114.PubMedCrossRefGoogle Scholar
  83. Stone M.H. (1989) The role of pharmacotherapy in the treatment of patients with bordeline personality disorder. Psychopharmacol Bull 25: 564–571.PubMedGoogle Scholar
  84. Tamminga C.A., Thaker G.K., Moran M., Kakigi T., and Gao X.M. (1994) Clozapine in tardive dyskinesia: observations from human and animal model studies. J Clin Psychiatry 55: 102–106.PubMedGoogle Scholar
  85. Verkes R.J., Fekkes D., Zwinderman A.H., Hengeveld M.W., Van der Maast R.C., Tuyl J.P., Kerkhof A.J., and Van Kempen G.M. (1997) Platelet serotonin and [3H]paroxetine binding correlate with recurrence of suicidal behavior. Psychopharmacology 132: 89–94.PubMedCrossRefGoogle Scholar
  86. Verkes R.J., Van der Maast R.C., Kerkhof A.J., Fekkes D., Hengeveld M.W., Tuyl J.P., and Van Kempen G.M. (1998) Platelet serotonin, monoamine oxidase activity, and [3H]paroxetine binding related to impulsive suicide attempts and borderline personality disorder. Biol Psychiatry 43: 740–746.PubMedCrossRefGoogle Scholar
  87. Watkins S.E., Callender K., Thomas D.R., Tidmarsh S.F., and Shaw D.M. (1987) The effect of carbamazepine and lithium on remission from affective illness. Br J Psychiatry 150: 180–182.PubMedCrossRefGoogle Scholar
  88. Wilcox J.A. (1995) Divalproex sodium as a treatment for borderline personality disorder. Ann Clin Psychiatry 7: 33–37.PubMedCrossRefGoogle Scholar
  89. Zanarini M.C., Gunderson J.G., Marino M.F. et al. (1988) DSM-III disorders in the families of borderline outpatients. J Personality Disord 2: 4292–4302.CrossRefGoogle Scholar
  90. Zanarini M.C., Gunderson J.G., and Frankenburg F.R. (1989) Axis I phenomenology of borderline personality disorder. Compr Psychiatry 30: 149–156.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1999

Authors and Affiliations

  • F. Benedetti
    • 1
  • C. Colombo
    • 1
  • L. Sforzini
    • 1
  • C. Maffei
    • 1
  • E. Smeraldi
    • 1
  1. 1.Istituto Scientifico Ospedale San Raffaele Department of Neuropsychiatric Sciences School of MedicineUniversity of MilanMilanoItaly

Personalised recommendations